The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index; 7 of the 15 sources its claims cite were checked for support.
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Open accessAbstract
BACKGROUND: Psilocybin is being studied for use in treatment-resistant depression. METHODS: In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support. The primary end point was the change from baseline to week 3 in the total score on the Montgomery-Åsberg Depression Rating Scale (MADRS; range, 0 to 60, with higher scores indicating more severe depression). Secondary end points included response at week 3 (≥50% decrease from baseline in the MADRS total score), remission at week 3 (MADRS total score ≤10), and sustained response at 12 weeks (meeting response criteria at week 3 and all subsequent visits). RESULTS: A total of 79 participants were in the 25-mg group, 75 in the 10-mg group, and 79 in the 1-mg group. The mean MADRS total score at baseline was 32 or 33 in each group. Least-squares mean changes from baseline to week 3 in the score were -12.0 for 25 mg, -7.9 for 10 mg, and -5.4 for 1 mg; the difference between the 25-mg group and 1-mg group was -6.6 (95% confidence interval [CI], -10.2 to -2.9; P<0.001) and between the 10-mg group and 1-mg group was -2.5 (95% CI, -6.2 to 1.2; P = 0.18). In the 25-mg group, the incidences of response and remission at 3 weeks, but not sustained response at 12 weeks, were generally supportive of the primary results. Adverse events occurred in 179 of 233 participants (77%) and included headache, nausea, and dizziness. Suicidal ideation or behavior or self-injury occurred in all dose groups. CONCLUSIONS: In this phase 2 trial involving participants with treatment-resistant depression, psilocybin at a single dose of 25 mg, but not 10 mg, reduced depression scores significantly more than a 1-mg dose over a period of 3 weeks but was associated with adverse effects. Larger and longer trials, including comparison with existing treatments, are required to determine the efficacy and safety of psilocybin for this disorder. (Funded by COMPASS Pathfinder; EudraCT number, 2017-003288-36; ClinicalTrials.gov number, NCT03775200.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
7 of 15 cited sources checked · 5 supported · 0 flagged · accuracy not yet measured
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Its potential antidepressant efficacy was suggested by preliminary studies involving patients with life-threatening cancer.[5][6][7]”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Abstract
What the sources say
- Not checked — no full text of the sourcecites [5] 5. Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced- stage cancer. Arch Gen Psychiatry 2011; 68: 71-8. source
- Supportedcites [6] 6. Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction follow- ing psilocybin treatment for anxiety and depression in patients with life-threaten- ing cancer: a randomized controlled trial. J Psychopharmacol 2016; 30: 1165-80. source
The Discussion (Primary outcomes) reports that psilocybin, given with psychotherapy, reduced depression in patients with life-threatening cancer. The Conclusions likewise describe rapid and sustained antidepressant effects while calling for further research to establish efficacy definitively. (LLM, conf=0.93)
- Supportedcites [7] 7. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threaten- ing cancer: a randomized double-blind trial. J Psychopharmacol 2016; 30: 1181-97. source
The Discussion reports that high-dose psilocybin decreased depressed mood in patients with a life-threatening cancer diagnosis. The Conclusions describe substantial, enduring decreases under psychologically supportive conditions, supporting the citing sentence’s cautious claim of potential antidepressant efficacy. (LLM, conf=0.94)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Amelioration of symptomatic depression in pilot studies of major depressive disorder, including those that compared psilocybin with escitalopram 8,9 and that investigated its use in treatment-resistant depression, 10 has suggested therapeutic potential for this agent.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Abstract
What the sources say
- Partly supportedcites [8] 8. Davis AK, Barrett FS, May DG, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry 2021; 78: 481-9. sourceExperimental — accuracy not yet measured
The Discussion and Conclusions report reduced depressive symptoms following psilocybin-assisted therapy in patients with major depressive disorder, supporting its therapeutic potential. But the Methods describe a delayed-treatment control, not an escitalopram comparison. The Discussion identifies treatment-resistant depression as the subject of a previous study, not this trial. No page numbers are available in our copy. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [9] 9. Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of psilocybin versus escital- opram for depression. N Engl J Med 2021; 384: 1402-11. source
- Supportedcites [10] 10. Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psycho- logical support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 2016; 3: 619-27. source
Citation 10 is attached to the treatment-resistant depression study, not the escitalopram comparisons cited as 8 and 9. The paper’s “Added value of this research” section (page not supplied) reports enduring reductions in symptom severity and says psilocybin might have value for treatment-resistant depression. (LLM, conf=0.93)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Pharmacokinetic research has shown dose-dependent increases in receptor occupancy and subjective effects of psilocybin across the dose range of 3 to 30 mg. 18”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Discussion
What the sources say
- Supportedcites [18] 18. Madsen MK, Fisher PM, Burmester D, et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor oc- cupancy and plasma psilocin levels. Neu- ropsychopharmacology 2019; 44: 1328-34. source
The Discussion states that psilocybin doses of 3–30 mg were associated with dose-dependent cerebral 5-HT2A receptor occupancy. It also reports that subjective intensity ratings were positively correlated with receptor occupancy and plasma psilocin levels, supporting the paraphrase about subjective effects. (LLM, conf=0.88)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Before the week 3 primary end-point assessment, initiation of treatment for depression was reported by 4 participants (5%) in the 25-mg group, 9 (12%) in the 10-mg group, and 14 (18%) in the 1-mg group.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > R esult s
Strength:plain· not yet calibratedn = 4Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and the difference between the 10-mg group and the 1-mg group was -2.5 (95% CI, -6.2 to 1.2; P = 0.18)”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Efficacy
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: The 1-mg dose of psilocybin is an inactive control that does not itself produce antidepressant effects.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No serious adverse events were reported from day 2 up to week 3 in the 1-mg group.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Safety
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were no serious adverse events reported on day 1.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Safety
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this trial of psilocybin administered in a single session with psychological support, a 25-mg dose but not a 10-mg dose resulted in a significantly greater reduction (improvement) in MADRS total scores than a 1-mg dose at 3 weeks in participants with treatment-resistant depression but was associated with adverse events.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: The 1-mg dose of psilocybin is an inactive comparator that does not produce therapeutic effects.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“included a trial population in which more than 90% of the participants did not have previous exposure to psilocybin”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The confidence interval for the odds ratio for sustained response at week 12 for both the 25-mg dose and the 10-mg dose as compared with the 1-mg dose included 1.”
- Also stated in: § Discussion · plain
“The confidence interval for the odds ratio for sustained response at week 12 for the 25-mggroup as compared with the 1-mg group included 1.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Efficacy
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § Discussion · plain
- Probably not a substantial claim. 18
- It may state two separate claims as one. 30
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Patients with treatment-resistant depression have greater severity and duration of illness, disability, physical illness, incidences of hospitalization, risk of suicide, and economic costs than patients with treatment-responsive depression.[1][2][3]”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Abstract
What the sources say
- Not checked — no full text of the sourcecites [1] 1. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905-17. source
- Not checked — no full text of the sourcecites [2] 2. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D project results: a comprehensive review of find- ings. Curr Psychiatry Rep 2007; 9: 449-59. source
- Could not verifycites [3] 3. Pigott HE. The STAR*D trial: it is time to reexamine the clinical beliefs that guide the treatment of major depression. Can J Psychiatry 2015; 60: 9-13. sourceExperimental — accuracy not yet measured
The Methods passages discuss STAR*D remission, relapse, and treatment dropout, but do not compare treatment-resistant with treatment-responsive patients on illness burden. Searches for severity, disability, physical illness, hospitalization, suicide, and economic costs found no passage making the claimed comparison in our copy. (LLM, conf=0.74)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
Every source the paper cites for this claim was checked and supports it.
In the paper
“The Structured Interview Guide for the MADRS provided structured probes to ensure standardization of administration and comprehensive coverage of the 10 questions.15”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Efficacy End Points
What the sources say
- Supportedcites [15] 15. Williams JB, Kobak KA. Development and reliability of a structured interview guide for the Montgomery Asberg De- pression Rating Scale (SIGMA). Br J Psy- chiatry 2008; 192: 52-8. source
The ‘Development of SIGMA probes and conventions’ section explicitly says that SIGMA provides structured probes to standardise administration and ensure comprehensive coverage of the scale’s ten items. It also describes questions for each item. (LLM, conf=0.95)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 79 participants were assigned to the 25-mg group, 75 to the 10-mg group, and 79 to the 1-mg group (Fig. 1).”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > R esult s
Strength:plain· not yet calibratedn = 79Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The least-squares mean change from baseline to week 3 in the MADRS total score was -12.0 points in the 25-mg group, -7.9 in the 10-mg group, and -5.4 in the 1-mg group.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Efficacy
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The incidence of response at week 3 was 37% in the 25-mg group, 19% in the 10-mg group, and 18% in the 1-mg group (odds ratio in the 25-mg group vs. the 1-mg group, 2.9 [95% CI, 1.2 to 6.6]; odds ratio in the 10-mg group vs. the 1-mg group, 1.2 [95% CI, 0.5 to 3.0])”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The 1-mg dose of psilocybin is an inactive control that does not itself produce antidepressant effects.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After week 3 and up to week 12, the number of participants initiating a treatment for depression was 26 (33%) in the 25-mg group, 18 (24%) in the 10-mg group, and 16 (20%) in the 1-mg group.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > R esult s
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The incidence of remission at week 3 was 29% in the 25-mg group, 9% in the 10-mg group, and 8% in the 1-mg group (odds ratio in the 25-mg group vs. the 1-mg group, 4.8 [95% CI, 1.8 to 12.8]; odds ratio in the 10-mg group vs. the 1-mg group, 1.2 [95% CI, 0.4 to 3.9]).”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The 1-mg dose of psilocybin is an inactive control that does not itself produce antidepressant effects.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All three had a history of suicidal behavior or nonsuicidal self-injury before the trial and did not have a treatment response at week 3.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Safety
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The incidence of sustained response at week 12 was 20% in the 25-mg group, 5% in the 10-mg group, and 10% in the 1-mg group (odds ratio in the 25-mg group vs. the 1-mg group, 2.2 [95% CI, 0.9 to 5.4];”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The 1-mg dose of psilocybin is an inactive control that does not itself produce antidepressant effects.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The serious adverse events in the 25-mg group were suicidal ideation (in two participants) and intentional self-injury (nonsuicidal self-injurious behavior) (in two participants) and in the 10-mg group were suicidal ideation (in two participants), intentional selfinjury (in one participant), and hospitalization (for severe depression, in one participant).”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Safety
Strength:plain· not yet calibratedn = 2Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No clinically significant changes in vital signs, clinical laboratory tests, or 12-lead ECGs were observed during the trial (see the Supplementary Appendix).”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Safety
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The incidences of response and remission at 3 weeks were generally in the same direction as the primary end-point results; however, the analyses of these end points were ordered in the prespecified hierarchical test procedure after the significance testing had terminated, and no definite conclusions can be drawn from these results.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Discussion
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The serious adverse events in the 25-mg group were suicidal ideation (in two participants) and intentional self-injury (nonsuicidal self-injurious behavior) (in two participants) and in the 10-mg group were suicidal ideation (in two participants), intentional selfinjury (in one participant), and hospitalization (for severe depression, in one participant).”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Safety
Strength:plain· not yet calibratedn = 2Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events occurred in 179 of 233 participants (77%) and included headache, nausea, and dizziness.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At the baseline visit, suicidal ideation (passive or active but with no intent or plan) was reported by 21 participants (27%) in the 25-mg group, 27 (36%) in the 10-mg group, and 19 (24%) in the 1-mg group.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Safety
Strength:plain· not yet calibratedn = 21Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After week 3 and up to week 12 (end of trial), severe adverse events were reported by 3% of the participants in the 25-mg group, 4% of those in the 10-mg group, and no participants in the 1-mg group.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Safety
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The number of participants who showed worsening of suicidal state from baseline to week 3 were 11 (14%) in the 25-mg group, 13 (17%) in the 10-mg group, and 7 (9%) in the 1-mg group (Table S8).”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Safety
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were rated as severe on day 1 were reported by 4% of the participants in the 25-mg group, 8% of those in the 10-mg group, and 1% of those in the 1-mg group.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Safety
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Secondary end-point results generally supported the primary analysis with the exception of 12week sustained response, at which time point the observed numerical difference was not considered to be statistically significant.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Just one participant (in the 25-mg group) was treated with adjunctive medication (lorazepam for acute anxiety) on day 1.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Safety
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition to headache, nausea, dizziness, and fatigue, some participants had suicidal ideation or self-injurious behavior, and the proportions of these participants were numerically higher in the 25-mg and 10-mg groups than in the 1-mg group.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events occurred in 66 participants (84%) in the 25-mg group, 56 (75%) in the 10-mg group, and 57 (72%) in the 1-mg group.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Safety
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Efficacy analyses were performed in the modified intention-to-treat analysis set, which included all randomly assigned participants who received treatment and had at least one postbaseline efficacy assessment.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Statistical Analysis
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“This was a phase 2 double-blind, dose-finding, parallel-group, randomized clinical trial.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Trial Oversight
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The nonsignificant finding for the comparison between the 10-mg group and the 1-mg group terminated significance testing on the basis of the prespecified hierarchical test procedure, and all the subsequent key secondary efficacy end points are considered to be not significantly different between the 25-mg group or the 10-mg group and the 1-mg group.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Efficacy
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All the therapists were unaware of the trial-group assignments, did not collect efficacy assessments, and were discouraged from speculating about doses.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Trial Design and Procedures
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“To control the overall type I error rate, a hierarchical test procedure was applied across the primary and three key secondary efficacy end points.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Statistical Analysis
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Ran-domization was performed at a central location and stratified according to country and the participant's previous experience with psilocybin.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Trial Design and Procedures
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“By week 12, a total of 5 participants (6%) in the 25-mg group, 9 (12%) in the 10-mg group, and 10 (13%) in the 1-mg group had withdrawn from the trial.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > R esult s
Strength:plain· not yet calibratedn = 5Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“An independent contract research organization (MedAvante-ProPhase) was responsible for assessment of participants using the Montgomery-Åsberg Depression Rating Scale (MADRS), 12 performed by trained remote raters who were unaware of the details of the trial and the trial-group assign-ments.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Trial Oversight
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These characteristics were similar to what has been observed in population studies involving persons with treatment-resistant depression, and the representativeness of the trial population is shown in Table S11.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > R esult s
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All the participants provided written informed consent.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Trial Oversight
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“The incidence of response at week 3 of 37% in the 25-mg group in our trial was numerically lower than that described for first-line treatment of major depressive disorder in several large trials of citalopram, 1 nefazodone, and escitalopram, sertraline, or venlafaxine 17 but was higher than the incidences of response reported in the STAR*D trial for second-line treatments and beyond.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Discussion
What the sources say
- Not checked — no full text of the sourcecites [1] 1. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905-17. source
- Not checked — no full text of the sourcecites [17] 17. Saveanu R, Etkin A, Duchemin A-M, et al. The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment. J Psy- chiatr Res 2015; 61: 1-12. source
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The manualized, time-limited approach to preparation, support, and integration of the psychedelic experience ensured safety and is not a stand-alone psychotherapy.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Discussion
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Limitations of the current trial include the lack of an active comparator, the lack of an ethnically diverse participant sample, and the exclusion of persons judged to be at a clinically significant risk for suicide.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We did not assess participants' ability to guess their dose assignment, and ensuring blinding is an inherent limitation of studies of drugs that produce psychedelic subjective effects.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The trial was conducted in accordance with the International Council for Harmonisation (ICH) Good Clinical Practice guidelines and the ethical principles of the Declaration of Helsinki.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Trial Oversight
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the 25-mg group, the incidences of response and remission at 3 weeks, but not sustained response at 12 weeks, were generally supportive of the primary results.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The 1-mg dose of psilocybin is an inactive control that does not itself produce antidepressant effects.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The trial protocol was approved by independent ethics committees or institutional review boards at each participating site.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Trial Oversight
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this phase 2 trial involving participants with treatment-resistant depression, psilocybin at a single dose of 25 mg, but not 10 mg, reduced depression scores significantly more than a 1-mg dose over a period of 3 weeks but was associated with adverse effects.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The 1-mg dose of psilocybin is an inactive control that does not itself produce antidepressant effects.
- Rests on an assumption: Participants remained unaware of their trial-group assignment (dose) during the trial.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These findings may explain the differences in efficacy between the groups in the current trial.”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“used remote raters who were unaware of the details of the trial and the trial-group assignments to determine the primary end-point measure (MADRS total score).”
§ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression > Discussion
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
The paper relies on this without support.
The 1-mg dose of psilocybin is an inactive control that does not itself produce antidepressant effects.
“1 mg (control)”
The paper relies on this without support.
Participants remained unaware of their trial-group assignment (dose) during the trial.
“This was a phase 2 double-blind, dose-finding, parallel-group, randomized clinical trial.”
The paper relies on this without support.
The 1-mg dose of psilocybin is an inactive comparator that does not produce therapeutic effects.
“The change from baseline to week 3 in the MADRS total score (primary end point) was significantly better with a 25-mg dose than with a 1-mg dose; there was not significant difference between the 10-mg dose and the 1-mg dose.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Among outpatient participants administered psilocybin, 3 of 553 participants (0.5%) experienced worsening suicidal ideation, with 1 such episode starting on the day of dosing.28”
From Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis (2024) · cites this paper as [28]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The 8% rate of severe adverse events in participants receiving psilocybin was similar to the 10% rate reported in the study by Goodwin et al in participants with TRD treated with a single 25-mg dose of psilocybin.14”
From Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial (2023) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Psychedelic-assisted therapy (PAT) with psilocybin and lysergic acid diethylamide (LSD) has demonstrated efficacy in the treatment of depression, anxiety, and some other neuropsychiatric disorders”
From Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response (2024) · cites this paper as Goodwin et al., 2022
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Eleven of these 23 (47.8%) had treatment-resistant depression and experienced a total of 17 SAEs over 12 weeks of follow-up, including suicidal ideation (5 events), suicidal behavior (3 events), nonsuicidal intentional self-injury (4 events), adjustment disorder (2 events), worsening depression (1 event), codeine withdrawal syndrome (1 event), and hospitalization (1 event).28”
From Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis (2024) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Participants receiving the 25 mg dose, but not the 10 mg dose, exhibited a significantly greater least- squares mean change from baseline to week 3 compared with the 1 mg dose.”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [274]
The cited source says what the claim attributes to it.
In the citing paper
“The response and remission rates for the participants receiving the 25 mg dose were 37% and 29%, respectively 274 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [274]
The cited source says what the claim attributes to it.
In the citing paper
“Larger recent studies have addressed these issues to various degrees, but report primary end points of short duration, 14,15 leaving open the question of the long-term clinical utility of psilocybin for an often chronic condition such as MDD.”
From Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial (2023) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Second, the use of niacin as active placebo may have increased believability of the comparator condition and enhanced the placebo response, given that placebo response rates in the current study were equivalent to those seen in response to a low-dose psilocybin comparator in participants with TRD and larger than the effect of an inactive placebo in a recent study in participants with MDD.14,15”
From Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial (2023) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Second, the use of niacin as active placebo may have increased believability of the comparator condition and enhanced the placebo response, given that placebo response rates in the current study were equivalent to those seen in response to a low-dose psilocybin comparator in participants with TRD and larger than the effect of an inactive placebo in a recent study in participants with MDD.14,15”
From Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial (2023) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Studies have used inactive placebos (e.g., [17, 35]), active placebos whose effects considerably differ from the acute effects of serotonergic psychedelics (e.g., [15, 36, 37]), or doses of psilocybin presumably too low to maintain blinding (e.g., [38, 39])”
The cited source says what the claim attributes to it.
In the citing paper
“which would theoretically not induce significant clinical benefits (e.g., [38] observed a significant decrease in depression symptomatology in participants with treatment-resistant depression after a single 25 mg dose relative to a 1 mg dose, but not with a 10 mg dose)”
The cited source says what the claim attributes to it.
In the citing paper
“Contemporary clinical studies have involved one to three dosing sessions (e.g., [38, 39, 117])”
The cited source says what the claim attributes to it.
In the citing paper
“Controlled clinical trials with psilocybin, as well as other psychedelics, have occasionally reported increases in suicidality after treatment, sometimes with extremely brief information about treatment-relatedness (Breeksema et al., 2022; Goodwin et al., 2022).”
From Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response (2024) · cites this paper as Goodwin et al., 2022
The cited source says what the claim attributes to it.
In the citing paper
“Research on MDD, anxiety and depressive symptoms associated with life-threatening cancer, and TRD showed the most robust evidence, supported by a non-randomized study 72 and several RCTs. 26,31-33,60,73-77”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [75]
The cited source says what the claim attributes to it.
In the citing paper
“Blinding procedures were not consistently robust, 26,32,60,72-76 and comparison with placebo or standard treatments was lacking in many studies. 25,26,31-33,39,57,60,72,73,75-81”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [75]
The cited source says what the claim attributes to it.
In the citing paper
“Psilocybin (4-phosphryloxy-N,N-dimethyltryptamine) is a serotonergic classic psychedelic (19–25) that has been examined in combination with psychological support as a promising treatment option in clinical trials for various disorders (26–28).”
In the citing paper
“Psychedelics such as psilocybin and lysergic acid diethylamide (LSD) are also novel therapeutics for MDD that show promise in clinical trials [124-126].”
From Beyond the serotonin deficit hypothesis: Communicating a neuroplasticity framework of major depressive disorder (2024) · cites this paper as [125]
Citations
Cites
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
(1998) · PubMed · Cited by 10,216
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 4×
“Any severe adverse event 7 (9) 5 (7) 1 (1)”
BackgroundInfluentialSelf-citationGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 1×
“Any severe adverse event 7 (9) 5 (7) 1 (1)”
BackgroundRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Self-citationTrial of Psilocybin versus Escitalopram for Depression
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032994 · Cited by 1,391
Self-citationEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Flagged first, then by citations
Cited by
Sorted by citations
Items 1,001–1,100 of 1,154
Rosa, W. E., Napolitano, S., McAndrew, N., Jenkins, B., Lichtenthal, W. G., Applebaum, A. J., BREITBART, W. S., & Agrawal, M. (2025) · Psychedelic Medicine · doi:10.1177/28314425251363983
Synthesis and Characterization of Psilocybin Metabolites and Deuterated Analogs
Williamson, S. E., Burkhartzmeyer, E. K., Faley, M. T., Ohana, R. F., Guzei, I. A., Valley, M., Cali, J. J., & Sherwood, A. M. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00879
Inhibition of cortico-amygdala projections underlies affective bias modification by psilocybinPreprint
Claydon, M. D. B., Hinchcliffe, J. K., Bartlett, J. M., Golden, C. T., Thomas, C. W., Gilmour, G., Mellor, J. R., Za, B., & Robinson, E. S. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.02.709133
Validation of the Korean version of the Self-Dehumanization Scale
Khosbayar, K., & Seo, J. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1754166
Effects of ayahuasca on neuropsychological performance and social cognition: A systematic review
de Paula, C. C., Vicentini, A. B., Guerra, L. T. L., Bouso, J. C., Hallak, J. E. C., & SANTOS, R. G. D. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261424212 · Cited by 1
Transient or transformative? Psychedelics, agency and informed consent
Caporuscio, C. (2026) · Journal of Medical Ethics · doi:10.1136/jme-2025-111248 · Cited by 1
“11 While many emphasise the role of therapy within psychedelic treatments, recent trials 12 have successfully attempted to minimise the role of active therapy and instead have minimal integration sessions to support participants in deriving their own insights and solutions from the experience.”
Mushroom biotech startups help address global challenges
Lurie‐Luke, E. (2026) · Nature Communications · doi:10.1038/s41467-026-70167-y
“Psilocybin induces transient disruption of rigid neural connectivity patterns associated with depression, facilitating emotional and cognitive fl exibility, thereby explaining its potential to alleviate symptoms in patients unresponsive to conventional treatments 82,83 .”
InfluentialPsychological support in psychedelic-assisted therapy clinical trials: A systematic review
Brusky, B., M’Baïlara, K., Alla, F., & Barrault, M. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261424204 · Cited by 1
Psychedelics and Mental Health in Endurance Athletes: A Cross-Sectional Study in Brazil
Portes, M. A. M., & Bertoglio, L. J. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2026.2644865
Trip killers: Addressing a critical knowledge gap in psychedelic research
O’Mahony, B. W., Harrington, C., Harkin, A., & Lally, N. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261431056
“For example, psilocybin, the psychoactive chemical found in “magic mushrooms,” has shown promise in alleviating treatment-resistant major depression (Carhart-Harris et al., 2021; Goodwin et al., 2022) and anxiety disorders (Griffiths et al., 2016).”
Skalski, P., Pękacka‐Falkowska, K., Pluto-Prądzyńska, A., & Owecki, M. K. (2026) · Brain Sciences · doi:10.3390/brainsci16040358
“While substances such as niacin [19], diphenhydramine [36], and low doses of psilocybin [23] have been employed in various studies, each of these options presents distinct limitations.”
InfluentialPsilocybin Attenuates Cortical Representations of Aversion in the Mouse Auditory CortexPreprint
Johnson, J. D., Tian, R., Etemadi, Y., & Li, Z. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.26.714498
“Growing evidence suggests that psilocybin may alleviate chronic and often treatment resilient psychiatric conditions marked by persistent negative affect and aberrant emotional learning, including depression, anxiety, and PTSD [6,9].”
Sleightholm, S., & O’Neill, C. (2026) · Psychological Reports · doi:10.1177/00332941261427381
Psychedelics and Their Clinical Use
Jeyakumar, S., & Messias, E. (2026) · Springer eBooks · doi:10.1007/978-3-032-15772-0_15
Stellmacher, J., Schmidt, C., Aicher, H., Eichel, K., Brakemeier, E., & Herwig, U. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1771726
“While recent studies assessing psychedelics in psychiatric indications have typically incorporated psychotherapeutic supervision within PAT protocols, they have largely concentrated on evaluating the pharmacological effects of the psychedelic substance itself (31, 32).”
Psychedelics in mental healthcare show growing interest but uneven evidence
Sarang, M., & Giorgi, R. D. (2026) · BMJ · doi:10.1136/bmj.s592
“For example, the largest phase 2b trial of 233 adults with treatment resistant depression found significantly greater reductions in depression, 4 however, a recent phase 2b trial of 144 adults with treatment resistant depression found only non-significantdifferencesinresponsetopsilocybin.”
Clinical Characteristics of Emergency Visits Related to Recreational Psychedelic Use
Bhatt, K. V., Friedman, J., Benster, L. L., Narasimhan, R., Yang, K., Mishra, J., Weissman, C. R., & Ramanathan, D. (2026) · Community Mental Health Journal · doi:10.1007/s10597-026-01620-x
“Recently, there has been a resurgence of interest from scientists and clinicians (Carhart-Harris & Goodwin, 2017; Goodwin et al., 2022 ; Griffiths et al., 2008 ; Raison et al., 2023 ) due to promising findings on their therapeutic effects in neuropsychiatric disorders, and the recognized need for…”
Psychedelic-assisted pharmacotherapy: clinical applications and regulatory considerations
Marazziti, D., Gambini, M., Gurrieri, R., Russomanno, G., Sità, G., Pescini, E., DIGIUSEPPE, F. R., & Mucci, F. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2654682 · Cited by 1
“Multiple phase 2 studies have shown that one or two high-dose psilocybin sessions, delivered with structured psychological support, can produce rapid and sometimes enduring reductions in depressive symptoms, with effect sizes that compare favorably with existing treatments [57,58].”
Cognition-enhancing drugs: current landscape, mechanisms, and future prospects
Zhang, M., Lin, C., Zhang, W., & Wang, X. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104665
Grant, J. E., Boutouis, S., O’Brien, M., Avila, L., Neelapu, M., & Ehsan, D. A. (2026) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000683
Halberstadt, A. L., & Young, J. W. (2026) · Neuropharmacology · doi:10.1016/j.neuropharm.2026.110972
Meshkat, S., Jha, M. K., & Bhat, V. (2026) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20250043
Aday, J. S., Glynos, N. G., Baker, A. K., Pouyan, N., Smith, T., Barron, J., Herberholz, M., Kruger, D. J., Woolley, J. D., & Boehnke, K. F. (2026) · Scientific Reports · doi:10.1038/s41598-026-48084-3 · Cited by 1
Self-citationResetting the default in the psychedelic renaissance
Thomas, S. T. (2026) · BioSocieties · doi:10.1057/s41292-026-00385-6
Viniegra, J. P. B. (2026) · Cureus · doi:10.7759/cureus.107343
“However, these approaches remain investigational, and further research is required to establish long-term safety and clinical applicability [26].”
Psychedelics and Autism Therapy: A Review of Current Research and Future Directions
Gondi, C. S., Gnanamony, M., Gondi, T. P., Nersesyan, L., & Demirkhanyan, L. H. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48040417
Hinchcliffe, J. K., Bartlett, J., Thomas, C. W., Golden, C. T., Gilmour, G., Bortolotto, Z., & Robinson, E. S. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.20.719483
Low, Z. X. B. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111717 · Cited by 2
Psychedelics: Future Therapeutics in Major Depression?
Olivier, B., & Olivier, J. D. A. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-981-95-6872-7_25
Nayak, S. M., Sepeda, N. D., Dick, M. N., Tiwari, P., Zahid, Z., Sayalı, C., Weiss, B., Yaden, D. B., Garcia‐Romeu, A., Barnett, B. S., et al. (2026) · medRxiv · doi:10.64898/2026.04.28.26351625
D’Amelio, T. A., Garbagnoli, T. G., Cuello, J. R., Lewis-Healey, E., Pallavicini, C., Cavanna, F., Bruno, N. M., de la Fuente, L. A., Muller, S. A., Copa, D., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.30.721872
Exploring new avenues: Psychedelic‐assisted therapy for young people
Vamvakopoulou, I. A., Nicholls, D., Nutt, D. J., & Simplicio, M. D. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70579
Walters, C. K., Chetty, S., Rants’o, T. A., Gossayn, S., & Lerotholi, L. J. (2026) · Research Square · doi:10.21203/rs.3.rs-9283280/v1
Jóźwiak-Bębenista, M., Stasiak, A., Sienkiewicz, M., Kwiatkowski, P. A., & Kowalczyk, E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104229 · Cited by 1
“A larger phase 2b study found that a single 25 mg session produced the greatest short-term improvement at week 3, with between-group differences narrowing by week 12—useful context when setting expectations for durability after one dose [75].”
Prinz, S., & Aicher, H. (2026) · Suchttherapie · doi:10.1055/a-2670-0732
“Eine große Phase-IIb-Studie bestätigte die Wirksamkeit einer einzelnen moderaten Psilocybin-Dosis bei therapieresistenter unipolarer Depression [25].”
Penzenstadler, L. E., Brakha, T. A., & ZULLINO, D. F. (2026) · Suchttherapie · doi:10.1055/a-2599-1389
“22] sowie über Monate stabile Verbesserungen in onkologischen Ko-horten aufzeigen [23, 24].”
Psychedelic-assisted therapy: a survey on the clinical methods of Swiss physicians
Beichmann, K., Catzeflis, P., Aicher, H., Seragnoli, F., Calder, A. E., Amrani, A., & Hasler, G. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261448745 · Cited by 1
“Within our survey, most of the PAT patients had previous experience with psychedelics, which differs markedly from clinical research studies, 44,64 and could have affected the safety management and the therapeutic process.”
Hajivalizadeh, S., Farahmand, K., Kazemzadeh, K., Hajivalizadeh, G., & Shamabadi, A. (2026) · Cancer Reports · doi:10.1002/cnr2.70587
“Psilocybin is a tryptamine serotonergic psychedelic and 5-HT2A agonist that has antidepressant effects after a single dose and is also used in anxiety and post-traumatic stress disorder treat-ment [101–103].”
Psychedelics and neurostimulation for treatment resistant psychiatric disorders
Blažek, F., Látalová, K., Krahulík, D., & Hrabálek, L. (2026) · Discover Mental Health · doi:10.1007/s44192-026-00486-5
Emerging therapeutic opportunities for psychedelic and related drugs
Wonnacott, S., Stephens, G. J., & Sharp, T. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70485
“In particular, psilo-cybin has shown rapid-acting antidepressant activity in TRD (Alexander et al., 2026; Nutt et al., 2026), with one positive Phase II trial completed (Goodwin et al., 2022) and a Phase III trial reported to meet endpoints in the general press as of February 2026.”
Can Childhood be Used as a Model to Understand the Effects of Psychedelics?
Hurwitz, E. S., Dean, J. G., & Walker, C. M. (2026) · Topics in Cognitive Science · doi:10.1111/tops.70058
Bu, F., Qin, L., Zi-yang, L. O. U., Xie, Y., Zhang, S. Z., Xiong, L., & Wen, Y. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s609327
“32 For these reasons, psyche-delic-assisted therapy is best considered an emerging and highly supervised treatment model rather than a routine pharmacological option.”
Bertollo, A. G., Wippel, V. A., Mingoti, M. E. D., Prediger, R. D., & Ignácio, Z. M. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179036
Psychedelic-induced hypomania and mania: a systematic review and meta-analysis
Eskinazi, M., Nasserdine, R., Cusin, R. M., Baniotoupoulos, P., Saccaro, L. F., Pieri, M. D., Corino, T., Seragnoli, F., Briefer, J.-F., Brakha, T. A., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03657-6 · Cited by 2
“However, NCT05839509 was terminated due to regulatory and development strategy considerations.”
Hood, A., & Elkins, G. R. (2026) · Journal of Psychedelic Studies · doi:10.1556/2054.2026.00507 · Cited by 2
Rush, S., & Nasrallah, H. A. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2026.2675008
“The clinical findings summarized in Table 1 suggest that limited dosing sessions can produce rapid antidepressant responses in subsets of patients with TRD, although durability and generalizability remain under investigation [92–94].”
Effects of psilocybin on sleep quality and brain microstructure in chronic cluster headache
Brendstrup‐Brix, K., Ozenne, B., Fisher, P. M., Stenbæk, D. S., Petersen, A. S., Armand, S., McCulloch, D. E.-W., Marstrand-Joergensen, M. R., Larsen, S. M. U., Johansen, A., et al. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261449380
Houff, J., Williams, A., Allen, O., Gisabella, B., Pantazopoulos, H., & Arco, A. D. (2026) · European Journal of Neuroscience · doi:10.1111/ejn.70574
“therapeutic and/or behavioural effects (Goodwin et al. 2022; Knudsen 2023).”
Kelly, C. M., Fradet, M., Bostian, C. M., Donnelly, A. J., Ellis, S., Ostacher, M. J., Aaronson, S., & Suppes, T. M. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122063
Self-citationBoehnke, K. F., Pouyan, N., & Aday, J. S. (2026) · Drugs · doi:10.1007/s40265-026-02339-5 · Cited by 2
“There are several Phase II studies showing benefits of psilocybin-assisted therapy for depressive disorders [60, 62, 157], with Phase III trials currently ongoing.”
From Resistance to Redesign—The Emerging Logic of Hybrid Care in Treatment-Resistant Depression
Mucci, F., Gurrieri, R., Bouanani, S., Gambini, M., Russomanno, G., & Marazziti, D. (2026) · Brain Sciences · doi:10.3390/brainsci16060612
“…and specified the MADRS change at week 3 as the primary endpoint; least squares mean change favored 25 mg over 1 mg ( − 12.0 vs. − 5.4; difference − 6.6 [95% CI, − 10.2 to − 2.9]), with separation detectable as early as day 2, while 10 mg did not differ from 1 mg at the primary time point [22].”
InfluentialKervadec, E., Pauline, M., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Piolino, P., Benyamina, A., Roméo, B., & Hacquet, R. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111770
Mingardi, J., Molteni, R., & Bifari, F. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108290
Jajcay, N., Vejmola, Č., Korčák, J., Tylš, F., Viktorinová, M., Viktorin, V., Bravermanová, A., Androvičová, R., Balíková, M., Horáček, J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.09.731183 · Cited by 1
Self-citationLabra-Lorenzana, A., Lima-Sánchez, D. N., Delaflor-Wagner, C. A., Martínez-Hernández, D. G., Ramos-Jiménez, C., & Toledo-Lozano, C. G. (2026) · Psychiatry International · doi:10.3390/psychiatryint7030137
“…showing a large standardized residual (3.30) and near-zero covariance ratio; Davis [10], with two flagged effect sizes (DFFITS = − 2.38 and 1.33); and Goodwin [5], an extreme outlier in the between-subjects subgroup (standardized residual = − 5.75, covariance ratio = 0.001), as shown in Figure 5.”
InfluentialModlin, N. L., Elek, Z., Maggio, C., Agrawal, M., Lepow, L., Rucker, J., Stubley, J., & Guss, J. R. (2026) · Psychodynamic Psychiatry · doi:10.1521/pdps.2026.54.2.338
Self-citationSabani, A., & Khatak, A. (2026) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000005244
“Although these reactions are typically self-limited, the intensity of the experience necessitates continuous monitoring and structured psychological support [ 3 , 5 ] .”
Psychedelics, the media portrayal and large-language model evaluations
Clelland, C. L. T. (2026) · BJPsych Open · doi:10.1192/bjo.2026.12025
DESI-MSI-Based Multi-Organ Distribution Mapping of Psilocin in Zebrafish
Dong, M., Zhang, Y., Cao, M., Shi, T., Li, L., Zong, X., & Wang, C. (2026) · Molecules · doi:10.3390/molecules31122143
“…multiple recent randomized controlled trials and systematic reviews have demonstrated that psilocybin combined with psychotherapy produces significant and sustained efficacy in treatment-resistant depression, end-of-life anxiety, substance use disorders and post-traumatic stress disorder [9–12].”
Multi-metric evaluations of acute psychedelic effects on fMRI brain entropy
McCulloch, D. E.-W., Olsen, A. S., Ozenne, B., Larsen, K. O., Stenbæk, D. S., Armand, S., Madsen, M. K., Knudsen, G. M., & Fisher, P. M. (2026) · Nature Communications · doi:10.1038/s41467-026-74215-5 · Cited by 29
Guidetti, C., D, M. F. M., & Papakostas, G. I. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03722-0 · Cited by 1
Brar, P. S., Price, R. B., Ross, S., Tofighi, B., & Sarpal, D. K. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261456191
“…naturally produced species of fungi, which has been examined as a treatment for a range of psychiatric conditions (Bogenschutz et al., 2022; Carhart-Harris et al., 2021; Davis et al., 2021a; Goodwin et al., 2022; Griffiths et al., 2016; Moreno et al., 2006; Raison et al., 2023; Ross et al., 2016).”
The purpose of the psychosocial protocol in the psychedelic-assisted therapy: A scoping review
Ferreira, F. G. D. P., Fernandes, J. A. B., Filev, R., da Silveira, D. X., & Fidalgo, T. M. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261453850
Du, Y. J., Zhao, X., Yao, Y., Li, Y., Wang, G., & Zhang, L. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261453819
Estela-Fernandez, C. A., Elsheikh, R. M. Y., Beatrice, D. F., Alhendal, A. A., Ewe, C. I., Montesinos, S. Y., Wensel, J., Mishra, A. P., Yousif, A. A., & Ali, H. T. (2026) · Neuropsychiatrie · doi:10.1007/s40211-026-00584-4
Sjöström, D. K., Rybäck, O. S., Claesdotter‐Knutsson, E., Kajonius, P., Sondén, O. J., Carlbring, P., Björkstrand, J., & Movahed, P. (2026) · PLoS ONE · doi:10.1371/journal.pone.0352246
“Contemporary clinical trials have emphasized the role of structured psychological support and stable post-session environments in optimizing safety and therapeutic benefit [103].”
Usos recreativos, medicinales y etnobotánicos de hongos alucinógenos: una revisión
Chillogallo–Torres, É. A., Calle‐Morán, M. D., Cando–Andrade, K. P., Morocho-Malla, Á. R., & Luzuriaga-Rodríguez, E. N. (2026) · Multidisciplinary Collaborative Journal · doi:10.70881/mcj/v4/n3/164
Pasquini, L., Vohryzek, J., Escrichs, A., Perl, Y. S., Ponce‐Alvarez, A., Idesis, S., Girn, M., Roseman, L., Mitchell, J., Gazzaley, A. H., et al. (2026) · Human Brain Mapping · doi:10.1002/hbm.70596 · Cited by 8
“…profound long-term changes across these various psychiatric conditions, which range from alle-viation of anhedonia and apathy (Carhart-Harris et al. 2016, 2021; Goodwin et al. 2022), to reduced substance craving (Bogenschutz 2022; Johnson et al. 2017), and increased openness (Nour et al. 2017).”
Self-citationLodetti, G., de Bitencourt, R. M., Inserra, A., Redivo, H., Teixeira, A. G., de Farias, A. C. S., Pickler, K. D. P., Rohling, J. P. V., Endler, A. T., Zampronio, E. P., et al. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111817
CSF galanin and noradrenaline downregulation by psilocybin therapy in major depressive disorder
Pasławski, W., Doyon, D., Ekman, C. J., Yngwe, H., Mamula, D., Zarȩba-Pasławska, J., Beckman, M., Xu, Q., Hökfelt, T., Tiger, M., et al. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02490-3
“As a preferential 5-HT2A receptor agonist, acting via its active metabolite psilocin, psilocybin initiates a cascade of neurobiological effects culminating in rapid, substantial, and sustained reductions in depressive symptoms demonstrated in multiple randomized controlled trials [3 – 5].”
Liu, C. J., Ho, E. M., Enos, A. S., Baublyte, U. B., Luna, I. M., Kosche, A. R., & Sohal, V. S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.05.736652
“When psychedelic drugs are administered at sufficiently high doses, even just one or two treatments can induce long lasting improvements in mood and cognitive flexibility 9,10,35 .”
Psychedelics produce enduring enhancement of reward responsiveness in male rats
Thomas, C. W., LaMalfa, K. S., Whelan, T. P., Blackmore, T., Golden, C. T., Pizzagalli, D. A., Bergman, J., Gilmour, G., & Kangas, B. D. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02475-2 · Cited by 1
Systems-based psychiatry: insights from psychedelic research on mechanisms of healing
Shannon, S., & Weil, A. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1789902 · Cited by 1
“In contrast to conventional psychopharmacology, where sustained receptor occupancy is typically assumed to be necessary for therapeutic bene fi t, psychedelics can produce durable improvements following one or a few administrations (68 – 70).”
Hörnqvist, N. (2026) · Journal of Psychedelic Studies · doi:10.1556/2054.2026.00505
Meyer, T. D., Vale, L., Ibrahim, M., Olmos, C., Quevedo, J., & Soares, J. C. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-118471
“16 53 29 Davis et al started with a moderately high dose of psilocybin (20 mg) and then offered a higher dose (30 mg) which resulted in substantial and enduring antidepressant effects.”
Self-citationGould, T. D., Mathew, S. J., D, M. F. M., & Shekhar, A. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261456206 · Cited by 1
“Like ketamine, serotonergic psychedelics, such as psilocybin, have demonstrated rapid and long-lasting antidepressant effects following 1 or 2 doses (Carhart-Harris and Goodwin, 2017; Griffiths et al., 2016; Goodwin et al., 2022; Raison et al., 2023).”
The Evolution of Psychedelics and Psychedelic-Assisted Therapy
Brar, G., Lally, K., Kelly, J. R., & O'Connell, H. P. (2026) · Springer eBooks · doi:10.1007/978-3-032-27009-2_16
Self-citationFrom trial to clinic: psilocybin’s efficacy in routine treatment-resistant depression
Martiadis, V. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101780 · Cited by 2
Dougherty, R. F., Modlin, N. L., McGowan, N. M., Staples, P. C., Williams, E., Clarke, P., Shafiei, M., Leininger, C., Alti, M., Croal, M., et al. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261464988
Self-citationTrance practice and well-being measures: the case of Auto-Induced Cognitive TrancePreprint
Fernandez, A., Foncelle, A., Meunier, H., Revillet, F., & Breton, A. (2026) · medRxiv · doi:10.64898/2026.07.15.26358125
Reconstituting a two-step pathway for N,N-dimethyltryptamine (DMT) biosynthesis in bacteria
Junges, L. H., Degaut, F. L. D., Mota, F. J. T., Bruschi, G. P., Bonaldi, M. P. F., de Souza, E. M., & Müller‐Santos, M. (2026) · Metabolic Engineering Communications · doi:10.1016/j.mec.2026.e00286
Longitudinal neural and psychological changes following psilocybin under compassion imagery priming
Pallavicini, C., Llobenes, L., Cavanna, F., de la Fuente, L. A., Muller, S. L., Costa, M., Gumiy, N., Bruno, N. M., D’Amelio, T. A., Basran, J. K., et al. (2026) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2026.1874178
“Among these substances, psilocybin, found in certain species of mushrooms, has emerged as a promising candidate for mental health intervention (Griffiths et al., 2016; Goldberg et al., 2020; Carhart-Harris et al., 2021; Goodwin et al., 2022).”
Johnston, J. N., Jones, G. H., Peng, S., Yuan, P., Yavi, M., Kadriu, B., Henter, I. D., Quintanilla, B., Elkahloun, A. G., Moaddel, R., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03768-0
Integration in classic psychedelic-assisted therapies for mental health conditions: A scoping review
Vucak, N., Bruno, R., Quealy, J. J., Casimaty, J. G., Rossell, S. L., Castle, D. J., & Acevedo, N. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100030
Medicine 4.0: the era of revolutionary access
Macdonald, C. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1903811
Jones, G. H., Gilbert, J. R., Johnston, J. N., Akula, N., Schulmann, A., Arakelian, M. H., Peng, S., Yuan, P., Winful, E. A., Yavi, M., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03777-z
Cardiovascular safety of psilocybin in psychiatric practice: a narrative review
Szarpak, Ł., Pruc, M., Świeczkowski, D., Rybczynski, B., Pięta, A., & Cubała, W. J. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-026-04151-2
“Individual MDD and TRD trials similarly report transient session-related blood-pressure and pulse increases, while myocardial infarction, sustained arrhythmia, hypertensive emergency requiring critical care, or cardiac death have not been common in medically screened trial populations [ 1, 2, 4].”
Schmitz, C. N., Bernardic, M., Vlădoiu, A.-D., Harris, R., Carmana, D., Kärtner, L., Oberthür, G., Gründer, G., & Adolphi, H. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111873 · Cited by 1
Kuypers, K. P. C., Mason, N. L., Carlier, A., Totomanova, I., & Haijen, E. C. H. M. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03801-2 · Cited by 2
Einführung: Psychedelika in der modernen Medizin
Gründer, G., & Jungaberle, H. (2026) · Elsevier eBooks · doi:10.1016/b978-3-437-21293-2.00001-0
Mapping excitatory synaptic plasticity evoked by single-dose psilocybin in micePreprint
Li, Z., Weber, C., Sellitti, F., & Simmler, L. D. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.31.741703
Multidimensional characterization of the physiological and behavioral effects of TCB-2 in micePreprint
Yamamoto, M., Inoue, H., Hayashi, K., Aota, I., Matsumoto, J., Yamada, K., & Toda, K. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.01.742216
Wolf, R. C., Lambert, R., Shoar, S., Hunt, J. S., Donato, I., & Gandotra, N. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1900601
Die Rolle der Psychotherapie im Rahmen der Therapie mit Psychedelika
Wolff, M., Jungaberle, H., Evens, R., & Mertens, L. J. (2026) · Elsevier eBooks · doi:10.1016/b978-3-437-21293-2.00006-x
Berkovitch, L., & Charif, S. (2025) · Elsevier eBooks · doi:10.1016/b978-2-294-78794-2.00074-9
Feasibility and tolerability of psilocybin for phantom limb pain
Dean, J. G., Hurwitz, E. S., Furnish, T. J., Castellanos, J. P., McKinty, A., Farrell, B., Barrows, D., Peck, S. K., Trim, J., Samadhi, E., et al. (2026) · Journal of Pain · doi:10.1016/j.jpain.2026.106404
Potential Role of Psychedelics in the Treatment of Depressive Disorder
Wang, S., & Bahk, W.-M. (2026) · Springer eBooks · doi:10.1007/978-981-92-1331-3_12
Singh, A. N. A., Cook, K., & Hill, B. D. (2026) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-026-00393-0
“…contemporary clinical evidence base, including the Phase 3 trials of MDMA-assisted therapy for PTSD [8, 9] and randomized trials of psilocybin for major depressive and treatment-resistant depression [10, 11], alongside the FDA breakthrough therapy designations granted between 2017 and 2019 [1].”
Natural Products as GPCR-Targeting Antidepressant Candidates: Advances and Opportunities
Li, H., He, X., Cao, T., Huang, J., Chen, B., Xu, L., Yang, Y., Li, G., & Xiong, L. (2026) · Pharmaceuticals · doi:10.3390/ph19081275
“As a non-selective 5-HT2A receptor agonist, psilocybin has shown sustained efficacy in treating treatment-resistant depression in clinical trials [155,156].”
Levitt, S. E., Panko, L., Tsiandoulas, K., Forte, M., Costa, L., & Buchman, D. Z. (2026) · The Canadian Journal of Psychiatry · doi:10.1177/07067437261474291
Metadata
- Authors
- Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., Forbes, M., Haumann, H. M., Hellerstein, D. J., Hoppe, A. I., Husain, M. I., Jelen, L. A., Kamphuis, J., Kawasaki, J., Kelly, J. R., Key, R. E., Kishon, R., Knatz Peck, S., Knight, G., Koolen, M. H. B., Lean, M., Licht, R. W., Maples-Keller, J. L., Mars, J., Marwood, L., McElhiney, M. C., Miller, T. L., Mirow, A., Mistry, S., Mletzko-Crowe, T., Modlin, L. N., Nielsen, R. E., Nielson, E. M., Offerhaus, S. R., O’Keane, V., Páleníček, T., Printz, D., Rademaker, M. C., van Reemst, A., Reinholdt, F., Repantis, D., Rucker, J., Rudow, S., Ruffell, S., Rush, A. J., Schoevers, R. A., Seynaeve, M., Shao, S., Soares, J. C., Somers, M., Stansfield, S. C., Sterling, D., Strockis, A., Tsai, J., Visser, L., Wahba, M., Williams, S., Young, A. H., Ywema, P., Zisook, S., & Malievskaia, E.
- Affiliations
- King's College London (GB)
- SUNY Downstate Health Sciences University (US)
- From COMPASS Pathfinder (G.M.G., J.C.B., L.M., S.M., S.C.S., J.T., S.W., E.M.), the Department of Psychological Medicine, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London (C. Bird, L.A.J., G.K., L.N.M., F.R., J.R., S. Ruffell, M. Seynaeve, A.H.Y.), the National Institute for Health and Care Research Clinical Research Facility, King’s College Hospital NHS Foundation Trust (K.C.-C., J.C., A.D.), and South London and Maudsley NHS Foundation Trust, Bethlem Royal Hospital (L.A.J., L.N.M., J.R., A.H.Y.), London, and the Cumbria, Northumberland, Tyne and Wear Foundation Trust and Newcastle University, Newcastle (M.W.) — all in the United Kingdom; the Institute for Advanced Diagnostics and Therapeutics, Sheppard Pratt, Baltimore (S.T.A., M.F., T.L.M., S. Rudow); Sant Joan de Déu Hospital and the Sant Joan de Déu Research Foundation, Barcelona (O.A.); SUNY Downstate College of Medicine (P.C.A.), the New York State Psychiatric Institute (D.J.H., R.E.K., R.K., M.C.M., E.M.N.), and the Depa...
- University of California, San Francisco (US)
- Emory University (US)
- University Medical Center Groningen (NL)
- Duke University (US)
- ORCID
- Goodwin, Guy M.
- Aaronson, Scott T.
- Bird, Catherine
- Burke, Lisa
- Carhart-Harris, Robin
- Daniel, Aster
- DeBattista, Charles
- Dunlop, Boadie W.
- Eisen, Katherine
- Feifel, David
- Hellerstein, David J.
- Husain, Muhammad I.
- Jelen, Luke A.
- Kamphuis, Jeanine
- Kawasaki, Julie
- Kelly, John R.
- Kishon, Ronit
- Knight, Gemma
- Lean, Melanie
- Licht, Rasmus W.
- Marwood, Lindsey
- McElhiney, Martin C.
- Nielsen, René E.
- Nielson, Elizabeth M.
- O’Keane, Veronica
- Páleníček, Tomáš
- Repantis, Dimitris
- Rucker, James
- Ruffell, Simon
- Rush, A. John
- Schoevers, Robert A.
- Seynaeve, Mathieu
- Soares, Jair C.
- Somers, Metten
- Wahba, Mourad
- Williams, Samuel
- Young, Allan H.
- Zisook, Sidney
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-11-03
- Volume
- 387
- Issue
- 18
- Pages
- 1637-1648
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4308146982
- Cited by
- 1,167
- References
- 19
- Citations by year
- 2026: 275 · 2025: 327 · 2024: 333 · 2023: 216 · 2022: 15
- FWCI
- 203.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- COMPASS Pathfinder Limited
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- psilocybin, treatment-resistant depression, major depressive episode, single-dose administration, dose-response relationship, antidepressant efficacy, adverse events, suicidal ideation, psychedelic therapy
- MeSH terms
- Adult, Antidepressive Agents, Depression, Major Depressive Disorder, Double-Blind Method, Humans, Psilocybin, Treatment Outcome, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
